Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
2006 1
2015 2
2016 6
2017 7
2018 4
2019 7
2020 7
2021 11
2022 7
2023 13
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

71 results

Results by year

Filters applied: . Clear all
Page 1
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.
Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Blackwell KL, André F, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, Petrakova K, Hart LL, Villanueva C, Chan A, Jakobsen E, Nusch A, Burdaeva O, Grischke EM, Alba E, Wist E, Marschner N, Favret AM, Yardley D, Bachelot T, Tseng LM, Blau S, Xuan F, Souami F, Miller M, Germa C, Hirawat S, O'Shaughnessy J. Hortobagyi GN, et al. N Engl J Med. 2016 Nov 3;375(18):1738-1748. doi: 10.1056/NEJMoa1609709. Epub 2016 Oct 7. N Engl J Med. 2016. PMID: 27717303 Free article. Clinical Trial.
We randomly assigned the patients to receive either ribociclib (600 mg per day on a 3-weeks-on, 1-week-off schedule) plus letrozole (2.5 mg per day) or placebo plus letrozole. ...
We randomly assigned the patients to receive either ribociclib (600 mg per day on a 3-weeks-on, 1-week-off schedule) plus letrozole ( …
Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria.
Peffault de Latour R, Röth A, Kulasekararaj AG, Han B, Scheinberg P, Maciejewski JP, Ueda Y, de Castro CM, Di Bona E, Fu R, Zhang L, Griffin M, Langemeijer SMC, Panse J, Schrezenmeier H, Barcellini W, Mauad VAQ, Schafhausen P, Tavitian S, Beggiato E, Chew LP, Gaya A, Huang WH, Jang JH, Kitawaki T, Kutlar A, Notaro R, Pullarkat V, Schubert J, Terriou L, Uchiyama M, Wong Lee Lee L, Yap ES, Sicre de Fontbrune F, Marano L, Alashkar F, Gandhi S, Trikha R, Yang C, Liu H, Kelly RJ, Höchsmann B, Kerloeguen C, Banerjee P, Levitch R, Kumar R, Wang Z, Thorburn C, Maitra S, Li S, Verles A, Dahlke M, Risitano AM. Peffault de Latour R, et al. N Engl J Med. 2024 Mar 14;390(11):994-1008. doi: 10.1056/NEJMoa2308695. N Engl J Med. 2024. PMID: 38477987
The two primary end points in the first trial were an increase in the hemoglobin level of at least 2 g per deciliter from baseline and a hemoglobin level of at least 12 g per deciliter, each without red-cell transfusion; the primary end point for the second trial wa …
The two primary end points in the first trial were an increase in the hemoglobin level of at least 2 g per deciliter from baseline an …
Use of Rituximab in Childhood Idiopathic Nephrotic Syndrome.
Chan EY, Yap DY, Colucci M, Ma AL, Parekh RS, Tullus K. Chan EY, et al. Clin J Am Soc Nephrol. 2023 Apr 1;18(4):533-548. doi: 10.2215/CJN.08570722. Epub 2023 Feb 22. Clin J Am Soc Nephrol. 2023. PMID: 36456193 Free PMC article. Review.
Antibody-drug conjugates in lung cancer: dawn of a new era?
Coleman N, Yap TA, Heymach JV, Meric-Bernstam F, Le X. Coleman N, et al. NPJ Precis Oncol. 2023 Jan 11;7(1):5. doi: 10.1038/s41698-022-00338-9. NPJ Precis Oncol. 2023. PMID: 36631624 Free PMC article. Review.
Focal Adhesion Kinase (FAK)-Hippo/YAP transduction signaling mediates the stimulatory effects exerted by S100A8/A9-RAGE system in triple-negative breast cancer (TNBC).
Rigiracciolo DC, Nohata N, Lappano R, Cirillo F, Talia M, Adame-Garcia SR, Arang N, Lubrano S, De Francesco EM, Belfiore A, Gutkind JS, Maggiolini M. Rigiracciolo DC, et al. J Exp Clin Cancer Res. 2022 Jun 3;41(1):193. doi: 10.1186/s13046-022-02396-0. J Exp Clin Cancer Res. 2022. PMID: 35655319 Free PMC article.
In accordance with these data, we demonstrated the involvement of S100A8/A9-RAGE-FAK signaling in the control of Hippo/YAP activities, and we established the crucial contribution of RAGE-FAK-YAP circuitry in the growth and migratory effects initiated by S100A8/A9 in …
In accordance with these data, we demonstrated the involvement of S100A8/A9-RAGE-FAK signaling in the control of Hippo/YAP activities …
Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results.
Yap TA, Fontana E, Lee EK, Spigel DR, Højgaard M, Lheureux S, Mettu NB, Carneiro BA, Carter L, Plummer R, Cote GM, Meric-Bernstam F, O'Connell J, Schonhoft JD, Wainszelbaum M, Fretland AJ, Manley P, Xu Y, Ulanet D, Rimkunas V, Zinda M, Koehler M, Silverman IM, Reis-Filho JS, Rosen E. Yap TA, et al. Nat Med. 2023 Jun;29(6):1400-1411. doi: 10.1038/s41591-023-02399-0. Epub 2023 Jun 5. Nat Med. 2023. PMID: 37277454 Free PMC article. Clinical Trial.
Death following pulmonary complications of surgery before and during the SARS-CoV-2 pandemic.
STARSurg Collaborative and COVIDSurg Collaborative. STARSurg Collaborative and COVIDSurg Collaborative. Br J Surg. 2021 Dec 1;108(12):1448-1464. doi: 10.1093/bjs/znab336. Br J Surg. 2021. PMID: 34871379 Free PMC article.
RESULTS: This study included 7402 patients from 50 countries; 3031 (40.9 per cent) underwent surgery before and 4371 (59.1 per cent) during the pandemic. ...The pulmonary complication rate was similar (7.1 per cent (216 of 3031) versus 6.3 per cent (27 …
RESULTS: This study included 7402 patients from 50 countries; 3031 (40.9 per cent) underwent surgery before and 4371 (59.1 per …
Emerging Principles in the Transcriptional Control by YAP and TAZ.
Lopez-Hernandez A, Sberna S, Campaner S. Lopez-Hernandez A, et al. Cancers (Basel). 2021 Aug 23;13(16):4242. doi: 10.3390/cancers13164242. Cancers (Basel). 2021. PMID: 34439395 Free PMC article. Review.
This reveals how YAP/TAZ activation in cancer cells leads to extensive transcriptional control that spans several hallmarks of cancer. The definition of the molecular mechanism of transcriptional control and the identification of the pathways regulated by YAP/TAZ ma …
This reveals how YAP/TAZ activation in cancer cells leads to extensive transcriptional control that spans several hallmarks of cancer …
An Updated Understanding of the Role of YAP in Driving Oncogenic Responses.
Morciano G, Vezzani B, Missiroli S, Boncompagni C, Pinton P, Giorgi C. Morciano G, et al. Cancers (Basel). 2021 Jun 21;13(12):3100. doi: 10.3390/cancers13123100. Cancers (Basel). 2021. PMID: 34205830 Free PMC article. Review.
Yes-associated protein (YAP) has emerged as a key component in cancer signaling and is considered a potent oncogene. ...This review aims to summarize and present the state of the art knowledge about the role of YAP in cancer signaling, first focusing on how YAP …
Yes-associated protein (YAP) has emerged as a key component in cancer signaling and is considered a potent oncogene. ...This review a …
The biology of uveal melanoma.
Amaro A, Gangemi R, Piaggio F, Angelini G, Barisione G, Ferrini S, Pfeffer U. Amaro A, et al. Cancer Metastasis Rev. 2017 Mar;36(1):109-140. doi: 10.1007/s10555-017-9663-3. Cancer Metastasis Rev. 2017. PMID: 28229253 Free PMC article. Review.
Cytogenetic and molecular profiling allow for a very precise prognostication that is still not matched by efficacious adjuvant therapies. G protein signaling has been shown to activate the YAP/TAZ pathway independent of HIPPO, and conventional signaling via the mitogen-act …
Cytogenetic and molecular profiling allow for a very precise prognostication that is still not matched by efficacious adjuvant therapies. G …
71 results